Press release content from Globe Newswire. The AP news staff was not involved in its creation.

North Louisiana Forensic Science Center to host Cannabix Marijuana Breathalyzer Technology

PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
January 5, 2023 GMT

VANCOUVER, British Columbia, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it has entered into a memorandum of understanding with the North Louisiana Criminalistics Laboratory (NLCL) to host the Company’s technology for detection of ∆9-tetrahydrocannabinol (“THC”) in human breath. The Company’s proprietary laboratory-based marijuana detection equipment (as described below) will be used to analyze and confirm THC in breath samples captured in the field. In December, Cannabix delivered its MS Breath Sampler instrumentation to the Forensic Science Center in Shreveport, LA. Scientists will now be able to confirm THC in breath samples from various field studies at the Forensic Science Center’s state-of-the-art facility. The Company’s MS Breath Sampler is a new, simpler and effective way to test and confirm for THC in breath. The North Louisiana Criminalistics Laboratory, based in Shreveport, provides forensic science services in the areas of drug chemistry, DNA analysis, firearms examination, and forensic toxicology.


Joseph Jones, System Director at the NLCL, stated the following, “We are very pleased to be providing space within the Forensic Science Center for external vendors who are pursuing similar interests to our own efforts towards criminal justice and forensic science. We look forward to collaborating with Cannabix Technologies and housing their instrumentation as they work with individuals and groups across the country.”

Rav Mlait, CEO of Cannabix stated, “We are very excited to have our first installation of our MS Breath Sampler at the North Louisiana Criminalistics Laboratory. This technology is a major leap forward in laboratory analysis procedures for THC in breath samples. The Cannabix system requires no pre-preparation of samples and samples can be processed in under a minute. Furthermore, Cannabix has built a proprietary system that will allow for lab confirmation of breath samples from our FAIMS point of care system. The Company is seeking additional laboratory collaborators and welcome such interest.”


The Company’s handheld Breath Collection Unit (“BCU”, Fig. 1) and newly developed laboratory “MS Breath Sampler” (Fig. 2) are being used together to provide a new method for drug detection that complements gold-standard mass spectrometry (MS) and significantly simplifies laboratory analysis methods, reduces sample turnaround times (thus minimizing operating costs), while maintaining sensitive, precise results. By comparison, existing and legacy breath and saliva testing procedures require several sample extraction and preparation steps prior to analysis, and analysis itself can take from 1 - 3 hours per sample. This is expensive and impractical. Also, existing and legacy breath and saliva testing procedures tend to have inefficient, time-consuming collection methods, and recoveries are still often poor. Cannabix instrumentation is designed to be easy-to-use and seamlessly interfaced with techniques that toxicologists are already familiar with, requiring minimal training by all users.


The Company also reports that it has ended its license agreement with UBC and will move forward with its related device development using proprietary methods.

About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC - the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix devices are in the advanced prototype and pre-clinical testing stage.

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

Cannabix Technologies Inc.

For further information, contact the Company at


The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of marijuana breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.